Proteomics International has topped up its coffers with a $2.16 million cash boost from Australia’s research and development (R&D) tax incentive program that will help the company kick-off the commercial launch of its simple, innovative, precision diagnostic blood tests for diabetic kidney disease, endometriosis and oesophageal cancer.
The rebate, for the 2023-2024 financial year, has come as a direct result of the company’s $4.95m investment spend in R&D for its Promarker technology platform.
